News

March 21, 2019

PD-L1 Levels, Response to Tecentriq Linked in Younger Cancer Patients

News

Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have high ... Read more

March 19, 2019

CTCL Patients Who Continue Treatment Use Fewer Hospital Resources, Study Says

News

Patients with cutaneous T-cell lymphoma (CTCL) who for some reason discontinue their systemic treatments require more monthly emergency room visits, hospital admissions, and longer inpatient stays than those who continue ... Read more

March 15, 2019

Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage

News

The expansion stage of a Phase 1/2 trial testing tinostamustine in relapsed or refractory types of lymphoma and other blood cancers has enrolled a first patient. The study (NCT02576496) is currently ... Read more

March 13, 2019

Gamida Cell’s Therapy Shows Promise for Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Gamida Cell’s natural killer cell treatment is a promising approach to treat adults with relapsed or refractory non-Hodgkin’s lymphoma or multiple myeloma, according to early data from an ongoing Phase 1 clinical trial. ... Read more

March 12, 2019

Cell Medica Earns $8.7 Million Grant to Accelerate Off-the-shelf CAR-NKT Cell Therapy

News

Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 ... Read more

March 8, 2019March 8, 2019

Physician Stephen J. Forman Receives Top Honors for Research on Bone Marrow Transplantation

News

Stephen J. Forman, MD, a physician and researcher in bone marrow transplantation and disorders such as lymphoma, is racking up some accolades. Forman will receive the 2019 DKMS Mechtild Harf ... Read more

March 7, 2019

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

News

The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut ... Read more

March 5, 2019

PET Monitoring Can Be Used to Tailor Hodgkin’s Treatment, Trial Suggests

News

Monitoring Hodgkin’s lymphoma patients with positron-emission tomography (PET) scans during chemotherapy can help identify those who respond early to a more intense chemotherapy regimen and switch them to a softer, ... Read more

March 1, 2019

FDA Grants Priority Review for Revlimid-Rituxan Combo for Some Lymphomas

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Revlimid (lenalidomide) in combination with Rituxan (rituximab) for patients with previously treated follicular and marginal zone lymphoma. A decision ... Read more

February 28, 2019

First Patient Dosed in Trial of ADCT-402/Imbruvica Combo for Advanced DLBCL, MCL

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient ... Read more